~~<i id='63ECC2B671'><strike id='63ECC2B671'><tt id='63ECC2B671'><pre id='63ECC2B671'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

Wikipedia

author：entertainment 2025-10-01 10:59:05 - browse：67992

An FDA sign — health policy coverage from STAT — Sarah Silbiger/Getty Images

WASHINGTON — There’s about to be a new acronym in town.

The Food and Drug Administration is in the final stages of cementing sweeping changes to the Office of Regulatory Affairs, which oversees inspections and compliance for all its regulated products, according to three people familiar with the planning.

That overhaul includes a new name: Meet the Office of Inspections and Investigations.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Prosthetic arm enables patients to feel the objects they grip

knowledge

hotspot

leisure time

focus

Wikipedia

focus

EvangelineGallagher/TBIJAyearafteraninvestigationrevealedwidespreaduseofasubstandardcancerdrug,theWo

WSS

Scientists successfully use ultrasound imaging to map brain activity

Prosthetic arm enables patients to feel the objects they grip

Dark money group runs ads on China biotech bill

Adam's Biotech Scorecard: Do Sarepta's exon

Lab trade group sues FDA to halt regulation of lab

Biohaven protein

leisure time

Wikipedia

knowledge

Novavax promises a turnaround & Lilly roils the obesity market

David Sabatini, ex

Psychedelics group wrestles with new pharma identity

Health insurers say they are turning to AI to cut costs, improve care

Apple is now the first public company to be valued at $3 trillion

What will save rural psychiatry services? Higher Medicaid payments

George Santos makes 1st court appearance after pleading not guilty to 13 counts

CVS is on a mission to consolidate health care. Will it work?

BioMarin wins approval for gene therapy to treat hemophilia A

Stigma and the return of syphilis

hotspot

Stigma and the return of syphilis

To bolster infectious disease surveillance, genomics powerhouses team up

David Sabatini, ex

iTeos Therapeutics debuts first data on TIGIT

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

HPV vaccine, cervical cancer study delivers historic results

leisure time

focus

Wikipedia

focus